StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for FULC yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-19 | $6.04 | $5.91 | -2.15% | 0.5M |
| 05-20 | $5.97 | $6.35 | +6.37% | 0.5M |
| 05-21 | $6.31 | $6.59 | +4.44% | 0.4M |
| 05-22 | $6.72 | $6.57 | -2.23% | 0.3M |
| 05-26 | $6.58 | $6.73 | +2.28% | 0.3M |
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q3 2021 2021-09-30 |
|---|---|
Revenue | $7.80M |
Operating Income | $-57.49M |
Net Income | $-57.36M |
EPS (Diluted) | $-1.71 |
Total Assets | $255.55M |
Total Liabilities | $24.94M |
Cash & Equivalents | $65.47M |
Free Cash Flow OCF − CapEx | $-57.81M |
Shares Outstanding | 40.53M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.